About General Atlantic

General Atlantic is a leading global investor with more than four and a half decades of experience providing capital and strategic support for over 885 companies throughout its history. Established in 1980, General Atlantic continues to be a dedicated partner to visionary founders and investors seeking to build dynamic businesses and create lasting value. Guided by the conviction that entrepreneurs can be incredible agents of transformational change, the firm combines a collaborative global approach, sector specific expertise, a long-term investment horizon, and a deep understanding of growth drivers to partner with and scale innovative businesses around the world. The firm leverages its patient capital, operational expertise, and global platform to support a diversified investment platform spanning Growth Equity, Infrastructure, and Strategic Solutions. General Atlantic manages approximately $126 billion in assets under management, inclusive of all strategies, as of March 31, 2026, with more than 900 professionals in 20 countries across five regions. For more information on General Atlantic, please visit www.generalatlantic.com.

General Atlantic Life Sciences Practice

The GA Life Sciences practice provides capital and strategic support for development stage biopharma companies, with an established track record across public and private investments. The Life Sciences team focuses on novel therapies that provide substantial patient benefit and have the potential to redefine standards of care. GA’s differentiated approach to life sciences is characterized by highly thematic investing, scaling significant capital into companies as they advance through clinical development and commercialization, and partnering with management teams to generate value. Investments include Akero Therapeutics (acquired by Novo Nordisk), Karuna Therapeutics (acquired by BMS), Cincor Pharma (acquired by AstraZeneca), and Centessa Pharmaceuticals (potential acquisition by Eli Lilly).

Position Summary

General Atlantic is seeking a Life Sciences investor to join our New York‑based investment team. This role will have exposure to all parts of the investment process, including evaluating new investment opportunities and investment themes in biopharma and life science companies, conducting technical diligence, supporting deal execution, and working with portfolio companies. The ideal candidate will have a scientific background (MD or PhD) and at least two years of relevant industry experience, with the goal of driving strategic growth and generating value for the firm’s portfolio.

Responsibilities

Source, evaluate, and recommend investment opportunities in drug development / biopharmaceutical companies including development and ownership of thematic focus areas
Support scientific and clinical due diligence, integrating preclinical data, clinical trial results, regulatory strategy, and market dynamics into investment recommendations
Develop and present rigorous investment theses to senior stakeholders, including the global Investment Committee
Contribute across the full deal process, including coordination of third-party scientific advisors, KOLs, and commercial consultants
Monitor portfolio companies and support the GA team’s efforts in capital allocation and value creation
Leverage clinical and industry networks to generate proprietary deal flow and market intelligence
Collaborate with professionals across the firm and foster exceptional knowledge-sharing

Qualifications

MD or PhD in relevant scientific field (molecular biology, genetics, biology, chemistry, etc.)
2-5 years of post-graduate school professional experience, including at least 2 years of relevant experience in the life sciences sector (e.g., life sciences investing, life sciences strategy consulting, life sciences equity research / investment banking, biopharma operating role)
Ability to analyze and integrate data from various sources into investment recommendations, including preclinical and clinical data, FDA/regulatory correspondence, and market research
Strong foundation in financial modeling with a demonstrated commitment to deepening analytical expertise
Passion for primary scientific literature, including scientific/medical meetings and conferences
High degree of familiarity with drug development and regulatory processes
Excellent written and verbal communication skills, with the ability to synthesize and present complex information clearly
Demonstrated maturity and professional presence; comfortable interacting with senior executives and management teams
Highly motivated, inquisitive, and a positive, can-do attitude
Ability to take ownership, work independently, manage multiple priorities, and thrive in a fast-paced, entrepreneurial environment

GA Value

General Atlantic offers a robust reward program to all employees that will support you and your family, maintaining fulfilling, secure and healthy lives now and into the future, which includes but is not limited to medical insurance, retirement savings contributions, mental and physical health resources and an equal pay program that allows you to earn a base salary of $150,000 –160,000of which the exact amount offered will be driven by the degree to which you meet role requirements, additional special skills and experience. Additional reward programs, such as annual discretionary bonuses and long-term incentive programs, are available for eligible employees and are offered as recognition for performance and one’s contributions towards the organization’s success.

General Atlantic is an equal opportunity employer and does not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.

By completing this application, you are consenting to General Atlantic’s processing and use of your personal data. Information on how General Atlantic will use and process your data can be found here: https://www.generalatlantic.com/privacy-notice/

About the company

General Atlantic partners with high-quality growth companies worldwide, providing strategic and operational value-added support to help portfolio companies become market leaders and build long-term shareholder value. As a growth investor, it uses a collaborative, global approach with sector-specific expertise and macroeconomic growth insight to guide investments. Its team combines investment professionals with a Resources Group and Special Advisors to access a broad network and deliver integrated, customized support across regions and industries. The firm differentiates itself through hands-on collaboration, sector and regional know-how, and a track record of helping management teams scale businesses over time, aiming to achieve lasting leadership in their markets.

Company Size

501-1,000

Company Stage

N/A

Total Funding

$92.5B

Headquarters

New York City, New York

Founded

1980

Get referred to General Atlantic

See people who can refer or advise you

Simplify's Take

What believers are saying

AUM reached $130 billion by June 30, 2026, supporting larger fee pools.
GA closed Chariot Re's $700 million raise on September 2, 2026.
SambaNova and Blank Street financings in 2026 prove active deployment into hot sectors.

What critics are saying

King v. General Atlantic Service Company entered federal court on September 30, 2026.
Deutsche Börse bought GA's remaining ISS STOXX stake, removing a proven monetization engine.
A prolonged 2026 IPO drought traps GA's portfolio, crushing realizations and future fundraising.

What makes General Atlantic unique

GA spans Growth Equity, Credit, Energy Transition, and Infrastructure across 21 locations.
Its May 11, 2026 QIA partnership added $500 million and Middle East market access.
The September 1, 2026 625 Madison lease signals scale, permanence, and employer brand.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
401(k) Retirement Plan
Mental Health Support
Performance Bonus

Company News

Sports Business Journal

Oct 20th, 2026

NFL owners approve 32 Equity joint venture with General Atlantic to scale sports investing

NFL owners approved a joint venture between 32 Equity, the league's in-house investment platform, and private equity firm General Atlantic. Terms were not disclosed. The deal follows November talks about how to scale 32 Equity. The parties said they aim to broaden access to sports across global markets and back companies building new technologies, platforms, and experiences. The NFL founded 32 Equity in 2013, with each of its 32 teams giving $1 million to seed the fund. Two later capital calls grew it to about $250 million, not including investment returns. According to Pitchbook, it has invested in 42 companies, including Fanatics, On Location, and Clear. Sumit Varshney runs the platform, and PJT Partners advised it on the deal.

NeoFeed

Oct 14th, 2026

General Atlantic prepares IPO that could value asset manager at US$ 10 billion.

General Atlantic prepares IPO that could value asset manager at US$ 10 billion. American company resumes plans to go public in the first half of 2027 to finance business expansion Chat with Read the article summary General Atlantic, the American asset manager that manages more than US$ 130 billion in assets, has resumed plans to go public. The company is expected to be valued at up to US$ 10 billion in its initial public offering (IPO). The company had already taken the first steps toward a listing in 2023, but postponed the operation due to market conditions. Now, the offering is planned for the first half of 2027, according to information from the Financial Times (FT). The move is part of General Atlantic's strategy to finance business expansion and gain scale to compete with publicly traded rivals such as Blackstone, KKR and Apollo Global Management, in a private investment market estimated at US$ 24 trillion. Known for investing in technology and high-growth companies, the asset manager was one of the first investors in companies such as Facebook and Alibaba. In Latin America, General Atlantic has a history of investments in companies such as Mercado Livre, XP Investimentos, QuintoAndar and Kavak, a Mexican platform for buying and selling used vehicles. Follow Neofeed on social media and get more information. In the Brazilian market, it has also invested in businesses such as Neon, QI Tech, Arco Educação and Unico, in sectors ranging from financial services to education and technology. Over the last few years, General Atlantic has also expanded its operations beyond investments in growth companies. The asset manager acquired Iron Park Capital, specialized in credit, and Actis, focused on infrastructure, in addition to advancing into segments such as secondary investments and reinsurance. According to the FT, going public would allow it to accelerate this diversification and expand its service structure for institutional investors and high-net-worth individuals. The company also seeks to take advantage of interest in funds that invest in expanding companies without necessarily taking control of the businesses, in contrast to leveraged buyout deals. More recently, the asset manager even considered a stock market debut in the fourth quarter of 2026. However, it again postponed the plans due to factors such as market volatility and the geopolitical and macroeconomic context. In this scenario, the new timeline would allow the company to evaluate its 2026 financial results and the performance of a potential IPO by Anthropic before moving ahead with its own offering. There is still no definitive decision on the transaction, and the timeline may undergo further changes, according to the FT. General Atlantic did not comment on the matter. Chat with

Financial Times

Oct 14th, 2026

General Atlantic plans early 2027 IPO at up to $10bn valuation.

General Atlantic plans early 2027 IPO at up to $10bn valuation. Save over 40% on standard digital. $540 $299 for your first year. Save now on essential digital access to trusted FT journalism on any device. Savings based on monthly annualised price, offer ends 28th October.

JumpCloud

Oct 13th, 2026

JumpCloud Closes Out $225 Million Series F With Additional $66 Million Raised From Atlassian Ventures, CrowdStrike Falcon Fund, NTT Docomo Ventures, and Others

Learn how Atlassian Ventures, CrowdStrike Falcon Fund, NTT Docomo Ventures, and others are investing in JumpCloud.

CARE for Pets

Oct 2nd, 2026

GoodVets Acquires WellHaven Pet Health, adds 40+ veterinary hospitals.

GoodVets Acquires WellHaven Pet Health, adds 40+ veterinary hospitals. October 2, 2026 Admin GoodVets, recently ANNOUNCED that it has acquired WellHaven Pet Health (WellHaven), a network of over 40 veterinary hospitals operating across seven states. The transaction expands GoodVets' network from 75 to 116 hospitals and extends its presence across key regions in the United States, including the Pacific Northwest and Midwest. Financial terms of the transaction were not disclosed. Over time, each WellHaven hospital will transition to the GoodVets brand. * GoodVets Expands Its Relationship-Based Veterinary Care Model with WellHaven Pet Health (9.24.26) https://www.businesswire.com/news/home/20260924180902/en/GoodVets-Expands-Its-Relationship-Based-Veterinary-Care-Model-with-WellHaven-Pet-Health * GoodVets Acquires WellHaven Pet Health (9.24.26) https://www.martiscapital.com/goodvets-acquires-wellhaven-pet-health/ * Martis Captial founded WellHaven (Investment Date: July 2017) starting with a single hospital in Portland, Oregon, and supported the company's growth into a leading multi-regional veterinary platform. * GoodVets Announces Strategic Growth Investment from General Atlantic to Fuel Continued Expansion of Leading Veterinary Care Platform (9.13.23) https://www.businesswire.com/news/home/20230913197524/en/GoodVets-Announces-Strategic-Growth-Investment-from-General-Atlantic-to-Fuel-Continued-Expansion-of-Leading-Veterinary-Care-Platform * GoodVets announced it has received a strategic growth investment from General Atlantic, a leading global growth equity firm. General Atlantic joins existing investor SkyKnight Capital, L.P. ("SkyKnight"). * GoodVets Group Partners with SkyKnight Capital to Accelerate Growth and Build Leading, Modern Veterinary Care Platform (7.12.21) https://www.businesswire.com/news/home/20210712005207/en/GoodVets-Group-Partners-with-SkyKnight-Capital-to-Accelerate-Growth-and-Build-Leading-Modern-Veterinary-Care-Platform * SkyKnight Capital, L.P. ("SkyKnight"), a private equity firm, announced that it has made a growth investment into GoodVets Group LLC.

General Atlantic

Life Sciences Associate

About the job